WINNING THE BATTLE AGAINST SEPSIS
The first theranostic: EAA™ & Toraymyxin
PRESS RELEASE
Spectral Medical Provides Update on Favorable Tigris Clinical Trial Enrollment
Reports significant uptick in enrollment activities Tigris trial enrollment at 61 patients TORONTO, Ontario – May 30, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late...
Spectral Medical Hosts Successful Investigator Meeting; Expected to Help Bolster Enrollment Activities
Tigris trial enrollment at 60 patients. TORONTO, Ontario – May 24, 2023 - Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic...
INVESTOR UPDATE
April 6, 2023 Investor Day Presentation
EVENTS
2023 Annual General Meeting of Shareholders
Virtual Meeting June 7, 2023 at 4:00 PM ET